---
title: "Capecitabine"
slug: "capecitabine"
date: "2023-09-05"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[5-Fluorouracil]]

# Capecitabine

> "[[Xeloda]] Tablet" 500 mg/tab

- Dosing:
  - 1,000-1,250 mg/m2 PO twice daily Ã— 2 wks every 21 d.
  - Renal: CrCl 30-50 mL/min: 75% of dose; CrCl <30 mL/min: use contraindicated
- PK/PD:
  - Oral prodrug of 5-FU, converted via [[3-step activation process of Capecitabine|3-step activation process]] ó°’–.
  - Bioavailability âˆ¼80%, protein binding <60%, hepatic & tissue metabolism (active metabolite: 5-FU), renal excretion (96%), T1/2 0.5-1 h
- AEs:
  - Diarrhea,
  - [[hand-foot syndrome]],
  - myelosuppression,
  - mucositis,
  - neurologic tox,
  - coronary vasospasm
- DDI: Inhibits CYP2C9 weakly, warfarin (BBW), oral anticoagulants (â†‘ levels of anticoagulants), phenytoin (â†‘ levels of phenytoin), leucovorin (â†‘ tox of capecitabine)
- Clinical pearls: Increased risk of fatal/sev. AEs w/ DPD deficiency. Available as 150-mg & 500-mg tablets, take w/in 30 min after a meal, radiation sensitizer, uridine triacetate used as antidote in cases of overdose, accidental ingestion, & possible DPD deficiency

[[Three-step metabolic conversion of capecitabine to fluorouracil]]

---

- Used alone as adjuvant therapy following the complete resection of primary tumor in patients with stage III (Dukesâ€™ C) colon cancer when treatment with fluoropyrimidine therapy alone is â†’ preferred. [ref]
- Combined therapy with IV oxaliplatin
- is â†’ a reasonable choice (accepted, treatment option) as adjuvant therapy following complete resection of primary tumor in patients with stage III colon cancer. [ref]
- Initial (first-line) treatment of metastatic colorectal cancer when fluoropyrimidine therapy alone is â†’ preferred.
- Potential inhibition of CYP2C9.

## Contraindications

- Severe renal impairment (Clcr <30 mL/minute). [ref]
- Warnings/Precautions
  - Coagulopathy
  - Generally occurs within several days to months following initiation of therapy; similar events reported in at â†£ least a few patients within 1 month following discontinuance of therapy.
  - Alterations in anticoagulant effect associated with capecitabine therapy reported in patients with or without liver metastases. [ref]
  - Age >60 years and diagnosis of cancer are independent variables predisposing patients to an increased risk of coagulopathy. [ref]
  - Monitor anticoagulant response (PT or INR) frequently, and adjust the anticoagulant dose accordingly in patients receiving concomitant therapy. [ref](See Specific Drugs under Interactions.)
[[fluoropyrimidine]]

## ç¬¬ä¸‰ä»£ fluoropyrimidine è—¥ç‰© Capecitabine åœ¨çµè…¸ç›´è…¸ç™Œæ²»ç™‚ä¸­çš„ â†’ æ‡‰ç”¨ ğŸ©º

- Capecitabine æ˜¯å±¬æ–¼ç¬¬ä¸‰ä»£çš„ fluoropyrimidine è—¥ç‰©ï¼Œåœ¨2001å¹´è¢«ç¾åœ‹ FDA æ ¸å‡†ç”¨æ–¼çµè…¸ç›´è…¸ç™Œçš„ â†’ æ²»ç™‚ã€‚
- Capecitabine æœƒåœ¨è‚è‡Ÿä¸­ç¶“ç”± carboxylesterase æ°´è§£ï¼Œå†ç¶“ç”± cytidine deaminase è½‰æ›æˆ 5'-deoxy-5-fluorouridineï¼Œæœ€å¾Œåœ¨è…«ç˜¤ç´°èƒå…§ç”± thymidine phosphorylase å½¢æˆ5-FUã€‚
- é€™ç¨®é¸æ“‡æ€§çš„ â†’ ä»£è¬éç¨‹èƒ½è®“è…«ç˜¤ç´°èƒå…§èšé›†é«˜æ¿ƒåº¦çš„ â†’ 5-FUï¼Œæé«˜æŠ—ç™Œæ•ˆæœï¼ŒåŒæ™‚æ¸›å°‘ â†“ å…¶ä»–æ­£å¸¸ç´°èƒçš„ â†’ å±éšªæš´éœ²ï¼Œ âˆ´ å› æ­¤å‰¯ä½œç”¨ç›¸å°è¼ƒå°ã€‚
- Capecitabine çš„ â†’ åæ‡‰ç‡ç´„ç‚º24-35%ï¼Œæ•´é«”å­˜æ´»æ™‚é–“ç´„ç‚º11-20å€‹æœˆ
  - ä½µç”¨ LV æ•ˆæœä¸¦ âœ– ä¸æœƒæ›´å¥½ï¼Œ âˆ´ å› æ­¤æ¨™æº–ç™‚ç¨‹ä¸­ âœ– ä¸å»ºè­°åŠ å…¥ LVã€‚ ğŸ©º

## Capecitabine çš„ â†’ ä½œç”¨æ©Ÿåˆ¶ ğŸ§¬

- Capecitabine æ˜¯ä¸€ç¨® 5-FU å‰è—¥ï¼Œèƒ½å¤ è¿…é€Ÿåœ°è¢«å®Œæ•´åœ°å¸æ”¶ï¼Œä¸¦ç¶“éä¸‰æ­¥ä»£è¬ä½œç”¨è®Šæˆ 5-FUã€‚
  - å®ƒåœ¨è‚è‡Ÿä¸­è¢«é…¯æ°´è§£é…¶è½‰æ›ç‚º 5'-deoxy-5-fluorocytidineï¼Œ
  - ç„¶å¾Œåœ¨è…«ç˜¤å’Œè‚ç´°èƒä¸­è¢«èƒå˜§å•¶è„«æ°¨é…¶è½‰æ›ç‚º 5'-deoxy-5-fluorouridineï¼Œ
  - æœ€å¾Œç”±èƒ¸è…ºå˜§å•¶ç£·é…¸åŒ–é…¶è½‰æ›ç‚º 5-FUã€‚
- ç›¸æ¯”æ­£å¸¸çµ„ç¹”ï¼Œè…«ç˜¤ç´°èƒä¸­çš„ â†’ [[Thymidine phosphorylase]] èƒ¸è…ºå˜§å•¶ç£·é…¸åŒ–é…¶å«é‡æ›´é«˜ï¼Œ
  - âˆ´ å› æ­¤ Capecitabine èƒ½å¤ åœ¨è…«ç˜¤ç´°èƒä¸­ç”¢ç”Ÿ â†ª æ›´é«˜çš„ 5-FU æ¿ƒåº¦ï¼Œæé«˜æ²»ç™‚æ•ˆæœï¼ŒåŒæ™‚é™ä½ â†“ å°æ­£å¸¸çµ„ç¹”çš„ â†’ æ¯’å‰¯ä½œç”¨ã€‚

## Capecitabine åœ¨è½‰ç§»æ€§çµç›´è…¸ç™Œæ²»ç™‚ä¸­çš„ â†’ ç™‚æ•ˆè©•ä¼° ğŸ©º

- [Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials | British Journal of Cancer](https://www.nature.com/articles/6601676)
- æœ¬ç ”ç©¶åˆ©ç”¨ä¾†è‡ªå…©å€‹ç›¸åŒè¨­è¨ˆçš„ III æœŸç ”ç©¶ä¸­å¤§é‡ã€å…·æœ‰è‰¯å¥½ç‰¹å¾µçš„ â†’ è½‰ç§»æ€§çµç›´è…¸ç™Œ (mCRC) æ‚£è€…æ•¸æ“šï¼Œè©•ä¼°äº†å£æœ Capecitabine çš„ â†’ ç™‚æ•ˆã€‚
- ç¸½è¨ˆæœ‰1207åæœªæ¥å—éæ²»ç™‚çš„ mCRC æ‚£è€…è¢«éš¨æ©Ÿåˆ†é…åˆ°å£æœ Capecitabine (æ¯21å¤©å…©æ¬¡1250â€‰mgâ€‰m-2ï¼Œç¬¬1-14å¤©ï¼›n=603) æˆ–éœè„ˆ bolus 5-æ°Ÿå°¿å˜§å•¶/è‘‰é…¸éˆ‰ (5-FU/LVï¼›Mayo Clinic æ–¹æ¡ˆï¼›n=604) æ²»ç™‚ã€‚
- çµæœé¡¯ç¤ºï¼ŒCapecitabine çš„ â†’ åæ‡‰ç‡å„ªæ–¼ 5-FU/LV (26% vs. 17%ï¼›P<0.0002)
- äºçµ„åˆ†æè¡¨æ˜ï¼Œå³ä½¿åœ¨å…·æœ‰ âœ– ä¸è‰¯é å¾ŒæŒ‡æ¨™çš„ â†’ æ‚£è€…äºçµ„ä¸­ï¼ŒCapecitabine ä¹Ÿèƒ½å¤ ä¸€è‡´åœ°ç”¢ç”Ÿ â†ª æ›´å„ªç•°çš„ â†’ åæ‡‰ç‡ (P<0.05) ã€‚
- å„˜ç®¡å…©çµ„çš„ â†’ ä¸­ä½åæ‡‰æ™‚é–“å’ŒæŒçºŒæ™‚é–“ç›¸ä¼¼ï¼Œä½†ç–¾ç—…é€²å±•æ™‚é–“ (TTP) åœ¨å…©çµ„ä¸­ç›¸ç•¶ (é¢¨éšªæ¯” (HR) 0.997ï¼Œ95%ä¿¡å¿ƒå€é–“ (CI) 0.885-1.123ï¼ŒP=0.95ï¼›Capecitabine å’Œ 5-FU/LV çš„ â†’ ä¸­ä½ TTP åˆ†åˆ¥ç‚º 4.6 å’Œ 4.7 å€‹æœˆ) ã€‚
- å¤šè®Šé‡ Cox å›æ­¸åˆ†æç¢ºå®šå¹´é½¡è¼ƒå°ã€è‚è½‰ç§»ã€å¤šè™•è½‰ç§»å’Œè¼ƒå·®çš„ Karnofsky è¡¨ç¾ç‹€æ…‹æ˜¯ TTP ä¸è‰¯é å¾ŒæŒ‡æ¨™çš„ â†’ ç¨ç«‹å› ç´ ã€‚
- å…©çµ„çš„ â†’ æ•´é«”ç”Ÿå­˜ç‡ç›¸åŒ (HR 0.95ï¼Œ95% CI 0.84-1.06ï¼ŒP=0.48ï¼›Capecitabine å’Œ 5-FU/LV çš„ â†’ ä¸­ä½ç”Ÿå­˜æœŸåˆ†åˆ¥ç‚º 12.9 å’Œ 12.8 å€‹æœˆ) ã€‚
- Capecitabine èˆ‡ i.v. 5-FU/LV ç›¸æ¯”ï¼Œåœ¨ä½œç‚º mCRC çš„ â†’ ä¸€ç·šæ²»ç™‚æ™‚ï¼Œç”¢ç”Ÿ â†ª äº†æ›´å„ªç•°çš„ â†’ åæ‡‰ç‡ã€ç›¸ç•¶çš„ TTP å’Œæ•´é«”ç”Ÿå­˜ç‡ï¼Œä¸¦å…·æœ‰æ›´å¥½çš„ â†’ å®‰å…¨æ€§å’Œä¾¿åˆ©æ€§
- å°æ–¼éœ€è¦æ°Ÿå˜§å•¶å–®ç¨æ²»ç™‚çš„ â†’ æ‚£è€…ï¼Œæ‡‰å¼·çƒˆè€ƒæ…®ä½¿ç”¨ Capecitabine
- åœ¨ I æœŸå’Œ II æœŸè©¦é©—å–å¾—é¼“èˆäººå¿ƒçš„ â†’ çµæœå¾Œï¼Œæ­£åœ¨é€²è¡Œ Capecitabine è¯åˆä¼Šç«‹æ›¿åº·ã€å¥§æ²™åˆ©éŠ¨å’Œæ”¾ç™‚çš„ â†’ éš¨æ©Ÿè©¦é©—
- Capecitabine æ˜¯å–ä»£ i.v. 5-FU ä½œç‚ºçµç›´è…¸ç™Œæ²»ç™‚åŸºç¤çš„ â†’ åˆé©è—¥ç‰©ã€‚
